Spanlecortemlocel clinical trials
Also written HSC835.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses spanlecortemlocel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Novartis Pharmaceuticals (3) · Magenta Therapeutics, Inc. (1)
Often tested with
Tested in the same studies.
Umbilical Cord Blood Transplantation (1)
Studies
Open first, then newest update. How each study uses spanlecortemlocel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)CompletedPhase 2Magenta Therapeutics, Inc.NCT03406962Written as MGTA-456
- Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood TransplantCompletedPhase 2Novartis PharmaceuticalsNCT01930162Written as HSC835
- Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedPhase 1/2Novartis PharmaceuticalsNCT01474681Written as HSC835
- Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)WithdrawnPhase 1/2Novartis PharmaceuticalsNCT02715505Written as Umbilical cord blood transplantation with HSC835
Given beside what is tested · 1 — spanlecortemlocel is usual care or a partner of the new treatment
Codes
What other systems call spanlecortemlocel · ClinicalTrials.gg INT016308
- UNII (FDA) D8O38M043DSPANLECORTEMLOCELOne source FDA
- NCI Thesaurus C111571SpanlecortemlocelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | D8O38M043D | SPANLECORTEMLOCEL | One source FDA |
| NCI Thesaurus | C111571 | Spanlecortemlocel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.